Qing Ye1, Hong-Lin Chen. 1. Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, People's Republic of China. pphss@126.com
Abstract
BACKGROUND: The aim of this meta-analysis was to summarize the efficacy and safety of bevacizumab in the treatment of ovarian cancer. METHODS: We sought to identify randomised controlled trials (RCTs) by searching PubMed and Web of Science. Outcomes were objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events. RESULTS: Four studies with 4,246 patients were included. Combination of bevacizumab and chemotherapy resulted in a statistically significant improvement in ORR (OR 2.165, 95 % CI 1.511-3.103) and in PFS (HR 0.691, 95 % CI 0.517-0.865), compared with chemotherapy alone. There was no evidence of a significant improvement in OS (HR 0.934, 95 % CI 0.826-1.041). It also had significantly increased risk of gastrointestinal events (OR 2.743, 95 % CI 1.580-4.763; P < 0.001), hypertension (OR 4.630, 95 % CI 3.737 to 5.737; P < 0.001), proteinuria (OR 4.872, 95 % CI 2.617-9.069; P < 0.001), and arterial thromboembolism (OR 1.994, 95 % CI 1.210-3.286; P = 0.007). CONCLUSION: This meta-analysis suggests that the addition of bevacizumab to chemotherapy offers meaningful improvement in objective response rate and progression-free survival in ovarian cancer treatment, but does not benefit overall survival. It also significantly increased the occurrence of gastrointestinal events, hypertension, proteinuria, and arterial thromboembolism.
BACKGROUND: The aim of this meta-analysis was to summarize the efficacy and safety of bevacizumab in the treatment of ovarian cancer. METHODS: We sought to identify randomised controlled trials (RCTs) by searching PubMed and Web of Science. Outcomes were objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events. RESULTS: Four studies with 4,246 patients were included. Combination of bevacizumab and chemotherapy resulted in a statistically significant improvement in ORR (OR 2.165, 95 % CI 1.511-3.103) and in PFS (HR 0.691, 95 % CI 0.517-0.865), compared with chemotherapy alone. There was no evidence of a significant improvement in OS (HR 0.934, 95 % CI 0.826-1.041). It also had significantly increased risk of gastrointestinal events (OR 2.743, 95 % CI 1.580-4.763; P < 0.001), hypertension (OR 4.630, 95 % CI 3.737 to 5.737; P < 0.001), proteinuria (OR 4.872, 95 % CI 2.617-9.069; P < 0.001), and arterial thromboembolism (OR 1.994, 95 % CI 1.210-3.286; P = 0.007). CONCLUSION: This meta-analysis suggests that the addition of bevacizumab to chemotherapy offers meaningful improvement in objective response rate and progression-free survival in ovarian cancer treatment, but does not benefit overall survival. It also significantly increased the occurrence of gastrointestinal events, hypertension, proteinuria, and arterial thromboembolism.
Authors: M B Hannouf; E Winquist; S M Mahmud; M Brackstone; S Sarma; G Rodrigues; P K Rogan; J S Hoch; G S Zaric Journal: Curr Oncol Date: 2017-10-25 Impact factor: 3.677
Authors: Fariba Ahmadizar; N Charlotte Onland-Moret; Anthonius de Boer; Geoffrey Liu; Anke H Maitland-van der Zee Journal: PLoS One Date: 2015-09-02 Impact factor: 3.240